The ability of spaceflight to enhance the efficacy of a recombinant attenuated Salmonella vaccine, or RASV, will be the focus of experiments conducted by Cheryl Nickerson and Roy Curtiss, of the Biodesign Institute at Arizona State University. The payload will be carried aboard the space shuttle Atlantis on its final mission to the International Space Station.